New Fully Automated Proximity Ligation Assays Aim to Simplify, Standardize Workflows
The new platform will help researchers better understand cell-to-cell interactions in tumor microenvironments, benefitting future development of targeted cancer therapies
Leica Biosystems, a global leader in anatomic pathology, and Navinci, a leader in developing innovative solutions for studying protein interactions, announce a strategic collaboration to drive innovation in cancer patient care. This partnership enables automated in situ proximity ligation assays on the BOND RX Fully Automated Research Stainer.
The use of spatial biology in translational research enables scientists to study tumor cells within their microenvironment and better understand cell-to-cell interactions. Navinci’s in situ proximity ligation assay extends the capabilities of traditional immunoassays to highlight protein interactions with high specificity and sensitivity such that the proximity and binding of one protein to another can be readily detected, localized, and quantified.
The goal of the collaboration between Navinci and Leica Biosystems is to automate Navinci’s two new assay solutions on the BOND RX advanced staining platform in order to simplify and standardize the assay workflow for all laboratories and researchers. This integration provides researchers with a powerful platform to streamline their exploration of protein interactions involved in the tumor microenvironment, ultimately improving our understanding of cancer biology.
“Leica Biosystems joining forces with Navinci is critical making this powerful technology more widely accessible and available for cancer research,” shared Rob Monroe, chief medical officer at Leica Biosystems.
“The combination of our high-quality BOND RX Fully Automated Research Stainer with Navinci’s assay-based solutions empowers researchers to better understand the intricacies of tumor–cell interactions, which will ultimately contribute to the identification of new targets for drug development and eventual new therapies for cancer patients.”
As part of this collaboration, Navinci is launching two innovative products: NaveniBright™ BOND RX HRP and Naveni® PD1/PD-L1 BOND RX.
These are the first fully automated in situ proximity ligation assays designed to deliver enhanced reproducibility and throughput.
- NaveniBright BOND RX HRP introduces a new assay, seamlessly integrating chromogenic readout automation on the Leica Biosystems BOND RX platform. Based on Navinci’s advanced Naveni® in situ proximity ligation technology, this in situ kit provides flexibility tailored to customers’ primary antibodies and targets.
- Naveni® PD1/PD-L1 BOND RX addresses a critical need in immuno-oncology by enabling specific detection of PD1/PD-L1 interactions in situ. This capability improves reproducibility and throughput, allowing researchers to study this key immune checkpoint in larger cohorts.
“We are thrilled to partner with the industry-leading Leica Biosystems,” says Robert Gunnarsson, CEO of Navinci. “This collaboration brings together our expertise in accurately studying protein interactions within tissue microenvironments and Leica Biosystems’ renowned automation capabilities.
“Together, we are providing the scientific community with groundbreaking tools to drive research forward and significantly advance patient care.”
For additional information about Navinci, Leica Biosystems, and the newly launched solutions, please visit leicabiosystems.com or navinci.se/technology/naveni-bond.
For Research Use Only. Not for use in diagnostic procedures.